DLL3 and neoplasm: Tarlatamab (AMG 757) is a bispecific T-cell engager molecule (BiTE) which binds both DLL3 and CD3, leading to T-cell-mediated tumor lysis irrespective of MHC class I expression which is frequently downregulated in patients with SCLC [83].